Skip header and navigation

1 records – page 1 of 1.

Overall Survival of Patients With ALK-Positive Metastatic Non-Small-Cell Lung Cancer in the Russian Federation: Nationwide Cohort Study.
J Glob Oncol. 2019 May; 5:1-7
Publication Type
Journal Article
Ilya Tsimafeyeu
Fedor Moiseenko
Sergei Orlov
Elena Filippova
Alexander Belonogov
Aleksey Nebesnykh
Amir Khalimov
Elena Karabina
Valentina Shikina
Ahmed Abdelgafur
Galina Statsenko
Irina Titova
Dmitry Isaichikov
Galina Makarnyaeva
Aleksey Mordovskiy
Oksana Barkovskaya
Aleksey Smirnov
Marina Gikalo
Nikita Savelov
Dmitry Kosov
Evgeny Imyanitov
Irina Demidova
Sergei Tjulandin
Author Affiliation
1 Russian Society of Clinical Oncology, Moscow, Russia.
J Glob Oncol. 2019 May; 5:1-7
Publication Type
Journal Article
The overall survival (OS) results in patients with ALK-positive metastatic non-small-cell lung cancer (NSCLC) have rarely been reported. The aim of this prospective-retrospective cohort study was to obtain real-world data on the use of crizotinib or chemotherapy in patients with ALK-positive metastatic NSCLC in Russia.
Patients with epidermal growth factor receptor-negative metastatic NSCLC were screened in 23 cancer centers. To be eligible, patients were required to have confirmation of ALK rearrangement. Patients were treated with crizotinib (250 mg twice daily; n = 96) or the investigator's choice of platinum-based chemotherapy (n = 53). The primary end point was OS.
A total of 149 ALK-positive patients were included. Mean age was 53 years in both groups. Patients were predominately women (59%) and never-smokers (74%), and most patients had adenocarcinoma histology (95%). At a median follow-up time of 15 months, 79 of the 149 patients included in the analysis had died. Median OS from the start of treatment was 31 months (95% CI, 28.5 to 33.5 months) in the crizotinib group and 15.0 months (95% CI, 9.0 to 21.0 months) in the chemotherapy group (P
PubMed ID
31095455 View in PubMed
Less detail